Azathioprine withdrawn at month 27.The primary endpoint is the time to disease relapse (either minor or major relapse) from randomisation.Proportion of patients who maintain remission at 24 and 48 monthsCumulative accrual of damage as measured by the combined damage assessment score (CDA)Health-related quality of life as measured using SF-36Cumulative glucocorticoid (GC) exposure during the trialInfection (treated with intravenous or oral antibiotics) ratesCambridge University Hospitals NHS Foundation TrustKeywords provided by David Jayne, Cambridge University Hospitals NHS Foundation Trust:Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisPublications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
BioMed Central All will receive rituximab 375 mg/m2/week x 4 and glucocorticoids.Those patients that achieve disease control (BVAS/WG ≤ 1 and daily prednisone dose ≤ 10 mg) by month 4 will be randomised to the rituximab or control remission maintenance groups.Treatment is protocolised for the entire duration of the study, until the common close date, when the final patient recruited has completed 36 months within the study or until the patient has completed 48 months on study whichever the sooner. This occurs in at least half of patients within 2 years of receiving Rituximab. Unable to load your collection due to an error Patients will be in the trial for four years.The study has been designed by members of the European Vasculitis Study group (EUVAS) and the Vasculitis Clinical Research Consortium (VCRC).

Free PMC article We should also learn useful information about the effects of rituximab on quality of life and economic measures. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.If patients are aged over 60 years, reduce the dose by 25%.

Terrier B, Pagnoux C, Perrodeau É, Karras A, Khouatra C, Aumaître O, Cohen P, Decaux O, Desmurs-Clavel H, Maurier F, Gobert P, Quémeneur T, Blanchard-Delaunay C, Bonnotte B, Carron PL, Daugas E, Ducret M, Godmer P, Hamidou M, Lidove O, Limal N, Puéchal X, Mouthon L, Ravaud P, Guillevin L; French Vasculitis Study Group.Ann Rheum Dis. Epub 2019 Jul 12.Lee JJY, Alsaleem A, Chiang GPK, Limenis E, Sontichai W, Yeung RSM, Akikusa J, Laxer RM.Pediatr Rheumatol Online J. The dose may vary on alternate days e.g. The patients in the rituximab and azathioprine groups will then be compared.

2019 Jun 26;17(1):31. doi: 10.1186/s12969-019-0343-4. 2017 Dec 14;7(12):e018748. After a time, its effect wears off and the disease can return. If their disease is under reasonable control after four months, further treatment with either rituximab (a single dose ever four months for two years) or azathioprine tablets will be chosen randomly. It will also tell us how long patients remain well after the repeated rituximab treatments are stopped, and if repeated rituximab is safe. BioMed Central All patients will be treated with rituximab and steroids and we anticipate that most will respond well. 2020 Sep;79(9):1243-1249. doi: 10.1136/annrheumdis-2019-216863. COVID-19 is an emerging, rapidly evolving situation. The trial results will help decide the best treatment for future patients who have their vasculitis initially treated with rituximab. RITAZAREM aims to recruit patients with established ANCA vasculitis whose disease has come back 'relapsing vasculitis'.
Free PMC article Objectives Evaluation of rituximab and glucocorticoids as therapy to induce remission after relapse in ANCA-associated vasculitis (AAV) in a prospective observational cohort of patients enrolled into the induction phase of the RITAZAREM trial. Epub 2014 Nov 14.Curr Rheumatol Rep. 2017 Feb;19(2):6. doi: 10.1007/s11926-017-0632-1.Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, Andrews J, Bruchfeld A, Camilleri B, Carette S, Cheung CK, Derebail V, Doulton T, Forbess L, Fujimoto S, Furuta S, Gewurz-Singer O, Harper L, Ito-Ihara T, Khalidi N, Klocke R, Koening C, Komagata Y, Langford C, Lanyon P, Luqmani RA, Makino H, McAlear C, Monach P, Moreland LW, Mynard K, Nachman P, Pagnoux C, Pearce F, Peh CA, Pusey C, Ranganathan D, Rhee RL, Spiera R, Sreih AG, Tesar V, Walters G, Weisman MH, Wroe C, Merkel P, Jayne D; RITAZAREM coinvestigators; RITAZAREM co-investigators.Ann Rheum Dis. Artane, sometimes spelled Artaine (Irish: Ard Aidhin), historically Tartaine is a northside suburb of Dublin city, Ireland.It is also a civil parish in the ancient barony of Coolock.

This site needs JavaScript to work properly. Epub 2018 May 3.Sanders JS, de Joode AA, DeSevaux RG, Broekroelofs J, Voskuyl AE, van Paassen P, Kallenberg CG, Tervaert JW, Stegeman CA.Nephrol Dial Transplant. Target dose is 2mg/kg; maximum daily dose is 200mg. doi: 10.1136/bmjopen-2017-018748.Nephron Clin Pract. Maintenance therapy with rituximab can prevent ANCA-associated vasculitis relapses more efficiently than azathioprine, data from a Phase 3 trial suggest. 愚民Artane.＠これで時計のない人も安心。 @Artanejp フォローしている フォローされている ブロックする 「敵を知り己れを知れば百戦危うからず」確か孫子の言葉だが或る意味人生訓／あな … Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in 2010.

You have reached the maximum number of saved studies (100).Please remove one or more studies before adding more. Epub 2020 Jun 24.Cochrane Database Syst Rev.